Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Pharma Mar News

    26,25 € 0,00% +0,00 €
    12:27:42 Uhr L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2P9YT
    ISIN: ES0169501022
    US-Symbol: PHMMF
    Typ: Aktie

    Pharma Mar News

    28.04.22 - PLX
    Pharma Mar Q1 Net Income EUR 22 Million; Revenue EUR 53 Million
    (PLX AI) – Pharma Mar says good performance of the oncology business led to recurring revenues (sales plus royalties), growing by 7% in the first three months of the year to EUR 46 ...
    01.04.22 - PLX
    Pharma Mar Subsidiary Starts Phase 3 Trial of Tivanisiran for Dry Eye Disease
    (PLX AI) – Pharma Mar says Sylentis, a subsidiary of Pharma Mar, initiates a new Phase III trial in the United States to evaluate the safety of tivanisiran in patients with dry eye disease. ...
    28.02.22 - PLX
    Pharma Mar 2021 Earnings Beat Expectations
    (PLX AI) – Pharma Mar FY net income EUR 93 million vs. estimate EUR 59 million. • FY revenue EUR 230 million vs. estimate EUR 210 million • FY EBITDA EUR 97.8 million vs. ...
    11.01.22 - PR Newswire
    Die Zeitschrift Life Science Alliance veröffentlicht die Ergebnisse von Plitidepsin bei Patienten mit COVID-19, die zusätzliche Daten zur antiviralen Aktivität gegen die Varianten Delta und Omikron enthalten
    Die Zeitschrift Life Science Alliance veröffentlicht die Ergebnisse von Plitidepsin bei Patienten mit COVID-19, die zusätzliche Daten zur antiviralen Aktivität gegen die Varianten Delta ...
    11.01.22 - PR Newswire
    Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants
    Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants PR ...
    11.01.22 - PR Newswire
    Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants
    Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants - ...
    11.01.22 - PLX
    Pharma Mar Says Plitidepsin Phase 1 Covid-19 Study Confirms in Vitro Activity Against Omicron, Delta
    (PLX AI) – Pharma Mar reports Pre-​clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19 in Life Science Alliance journal. • Pharma Mar confirms ...
    23.12.21 - PR Newswire
    PharmaMar unterzeichnet eine neue Lizenz- und Vermarktungsvereinbarung mit Eczacıbaşı für Lurbinectedin in der Türkei
    PharmaMar unterzeichnet eine neue Lizenz- und Vermarktungsvereinbarung mit Eczacıbaşı für Lurbinectedin in der Türkei PR Newswire
    22.12.21 - PR Newswire
    PharmaMar signs a new licensing and commercialization agreement with Eczacibasi for lurbinectedin in Turkey
    PharmaMar signs a new licensing and commercialization agreement with Eczacibasi for lurbinectedin in Turkey PR Newswire
    11.11.21 - PR Newswire
    PharmaMar unterzeichnet Lizenz- und Vermarktungsvereinbarung mit Lotus Pharmaceutical für Lurbinectedin in Taiwan
    PharmaMar unterzeichnet Lizenz- und Vermarktungsvereinbarung mit Lotus Pharmaceutical für Lurbinectedin in Taiwan PR Newswire
    11.11.21 - PR Newswire
    PharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in Taiwan
    PharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in Taiwan PR Newswire
    24.09.18 - PR Newswire
    PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer
    PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer PR Newswire
    06.09.18 - PR Newswire
    PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference
    PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-​cell Lung Cancer During the IASLC World ...
    03.08.18 - PR Newswire
    The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin
    The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin PR Newswire
    31.07.18 - PR Newswire
    PharmaMar kündet an, dass die ATLANTIS-Studie ihr Rekrutierungsziel erreicht hat
    PharmaMar kündet an, dass die ATLANTIS-​Studie ihr Rekrutierungsziel erreicht hat PR Newswire
    31.07.18 - PR Newswire
    PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment
    PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment PR Newswire
    31.07.18 - PR Newswire
    PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment
    PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment PR Newswire
    27.07.18 - PR Newswire
    PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe
    PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe PR ...
    27.07.18 - PR Newswire
    PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe
    PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe PR ...
    26.06.18 - PR Newswire
    PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan
    PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan PR Newswire

    Newssuche

    Videos

    newspaper
    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »